Since its advent, nanotechnologies are considered key enabling technologies that take advantage of a wide array of nanomaterials (NMs) for biomedical and industrial applications generating significant societal and economic benefits. However, such innovation increases human exposure to these substances through inhalation, ingestion or dermal contact raising public health concerns. Furthermore, the NMs’ specific physicochemical properties, that confer them unique beneficial characteristics, can also elicit nano-bio interactions leading to toxicity and concerns for public health. In addition, such properties can be affected by the surrounding matrix, particularly when incorporated in complex matrices such as food products, leading to secondary features potentially more relevant than primary characteristics for determining their toxicological outcome. These nano specific issues raise the question of whether the NMs may produce adverse outcomes that are not accounted for when using conventional toxicological approaches to assess their safety.Such uncertainties about the safety of NMs for human health and the environment may hamper a faster and more widespread exploration of their potentials. In response, the NMs definition has evolved, and nanotoxicology has developed towards new and more integrative approach methods to support regulatory and policy actions.This book provides a perspective on recent developments in the synthesis, application, and characterization of NMs and the related nanotechnologies, focusing on nanotoxicology for their accurate safety assessment early in the product development stage. The use of complex in vitro models, including multicellular systems and organoids, and “omics-based” approaches, such as transcriptomics or epigenomics, have greatly contributed to an in-depth understanding of the cellular and molecular mechanisms behind some NMs toxicity. Such mechanistic knowledge is equally addressed in this book and has set the basis for a predictive nanotoxicology approach building on adverse outcome pathways. In addition, considering the knowledge provided by the above-mentioned approaches, insights into risk assessment, standardization, and regulation of NMs are also included.Incorporating adequate nanosafety assessment early in the life-cycle of NMs will allow the implementation of the safe and sustainable-by-design paradigm enabling safety to keep pace with innovation.Chapters 10 and 15 are available open access under a Creative Commons Attribution 4.0 International License via link.springer.com.
Part 1 – Synthesis, application and characterization of nanomaterials. Nanotechnologies.Synthesis, application and characterization of nanomaterials. Nanotechnologies.
Challenges in Nanomaterials Characterization. José Catita, Faculty of Health Sciences • Fernando Pessoa University • Porto, Portugal
Nanotoxicological evaluation of biopolymeric nanocarriers: the first steps. Ana Bettencourt, Lídia Gonçalves. Research Institute for Medicines (iMed.ULisboa) • Faculdade de Farmácia • Universidade de Lisboa, Portugal
Lipid Nanoparticles for drug deliver: preparation and validation using in vivo Caenorhabditis elegans model. Luís Fonseca et al., Instituto Superior Técnico • Universidade de Lisboa, Portugal
Topical delivery of nanostructured lipid carriers loaded with lipophilic active compounds on a 3D reconstructed human epidermis model. Fátima Pinto et al., Department of Human Genetics • National Institute of Health Dr. Ricardo Jorge • Lisboa, Portugal
TEM Based Approaches for Size characterization of nanomaterials - Jan Mast. Trace elements and nanomaterials, Belgium.
Nanomaterials characterisation – a challenge in physiological conditions - Keld A. Jensen. National Research Centre for the Working Environment. Denmark.
Traceability of nanomaterials in consumer products - Pieter-Jan De Temmerman. Service Trace Elements and Nanomaterials, Veterinary and Agrochemical Research Centre (CODA-CERVA), Belgium.
Part 2- Nanotoxicology: concepts and methodologies for toxicity evaluation of the nanomaterials
A predictive toxicology approach to characterize potential respiratory effects of functionalized nanocellulose fibres. Maria João Silva et al., Department of Human Genetics • National Institute of Health Dr. Ricardo Jorge • Lisboa, Portugal
New “omics” approaches as a tool to explore mechanistic nanotoxicology. Célia Ventura et al., Department of Human Genetics • National Institute of Health Dr. Ricardo Jorge • Lisboa, Portugal
In vitro assessment of nanomaterials hazard – how the experimental approach can make a difference. Sónia Fraga et al., Department of Environmental Health • National Institute of Health Dr. Ricardo Jorge • Porto, Portugal
Cellular and molecular mechanisms of toxicity of ingested nanomaterials. Henriqueta Louro, Department of Human Genetics • National Institute of Health Dr. Ricardo Jorge • Lisboa, Portugal
Nanomaterials in foods and the standardized static in vitro digestion method: contributing to the study of the potential toxic effects. Carla Martins et al., Department of Food and Nutrition • National Institute of Health Dr. Ricardo Jorge • Lisboa, Portugal
Assessment of occupational exposure to nanomaterials - Hannu Norppa, Julia Catalan - Nanosafety Research Center, Finnish Institute of Occupational Health, FI-00250 Helsinki, Finland.
Impact of Food Matrix and Gastrointestinal tract on the Toxicity of Ingested Engineered Nanomaterials - Glen M. Deloid. Center for Nanotechnology and Nanotoxicology, Department of Environmental Health , Harvard T. H. Chan School of Public Health, United States.
Effects of Nanoparticles on Nervous System Cells - Vanessa Valdiglesias. Universidade da Coruña, Spain.
Flow Cytometry as a High-Throughput Approach for the Genotoxicity Testing of Nanomaterials - Ricard Marcos. Universitat Autónoma de Barcelona, Spain.
In vivo testing of nanomaterial safety - Valerie Féssard. French Agency for Food, Environmental and Occupational Health and Safety. France.
Human biomonitoring of workers exposed to nanomaterials - Daniela Pelclova. Charles University and General University Hospital in Prague, Czech Republic.
Toxicogenomics and nanotoxicology - Quaiser Saquib. King Saud University, Saudi Arabia.
Part 3 - Risk assessment, standardization and regulation of nanomaterials
Adverse Outcome Pathways (AOPs) development, a tool for predictive nanotoxicology. Dora Rolo et al., Department of Human Genetics • National Institute of Health Dr. Ricardo Jorge •Lisboa, Portugal
Nanomaterials, a new challenge in the workplace. Ana Rita Alberto, Instituto de Soldadura e Qualidade • Oeiras, Portugal
The use of Mode-Of-Action Model for Safety Evaluation of Nanomaterials - Jan van Benthem. Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Bilthoven, Netherlands
Nanomaterials on Their Ability to Enhance Allergic Airway Sensitisation - Susan Dekkers. National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Risk assessment of nanomaterials in food and feed - Francesco Cubadda. Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanità, Rome, Italy
Safety Assessment of Nanomaterials in Cosmetics - Maria Dusinska. Health Effects Group, Department of Environmental Chemistry, NILU- Norwegian Institute for Air Research, Kjeller, Norway
The establishment of guidelines for nanomaterials testing - Peter Kearns. Organisation for Economic Co-operation and Development (OECD), France
Final Remarks/ Epilogue
Wrap up on risk assessment of nanomaterials and its current challenges - Kirsten Rasmussen. European Commission, Italy.
Henriqueta Louro is a research scientist at the Research and Development Unit of the Department of Human Genetics of the National Institute of Health Dr. Ricardo Jorge (INSA, Lisbon, Portugal) and an integrated member of the Centre for Toxicogenomics and Human Health (ToxOmics, NOVA Medical School, NOVA University of Lisbon). She is graduated in Biochemistry (Faculty of Sciences, Lisbon University) and holds a Ph.D. in Public Health-Environmental and Occupational Health (Nova University of Lisbon). She is a Specialist in Human Genetics (Portuguese Ministry of Health), lecturer at the Toxicology and Health in the Master Course of Human Biology and Environment at the Faculty of Sciences (Lisbon University) and scientific supervisor of M.Sc. and Ph.D. theses. Her main field of research is genetic toxicology and human biomonitoring, with work published in many international peer-reviewed scientific journals, books and communications in international and national congresses. Presently, she participates in the Human Biomonitoring Initiative (HBM4EU) and is the responsible researcher for nationally funded projects on the nanosafety field. Additionally, she is a member of ISO/CEN Portuguese Technical Commission CT194- Nanotechnologies and of the Portuguese consortium for nanosafety, PtOnano.
Maria João Silva is the principal investigator of the Research Group in Genetic Toxicology at the Department of Human Genetics of the National Institute of Health Dr. Ricardo Jorge (INSA), Lisbon and co-leads the research line on Environmental and Genetic Determinants of Human Disease, Centre for Toxicogenomics and Human Health (ToxOmics), NOVA Medical School, NOVA University of Lisbon). She received her doctoral formation in Genetic Toxicology at INSA after graduation in Pharmaceutical Sciences, holds a specialization in Human Genetics, and is an European Registered Toxicologist. She is also an invited Professor in Master Courses at public and private Universities. Her main research interests comprise human and environmental genotoxicity, nanotoxicology, chemicals and mixtures toxicology, and human biomonitoring. She has been involved in several national and European Projects and currently coordinates the HBM4EU Project’s activities at INSA and nationally funded projects on the safety assessment of nanomaterials and nanotechnologies. She is an expert in the OECD Project 4.095, aimed at the development of the Guidance Document on the adaptation of the "In Vitro micronucleus assay (OECD TG 487) for Testing of Manufactured Nanomaterials”.
Since its advent, nanotechnologies are considered key enabling technologies that take advantage of a wide array of nanomaterials (NMs) for biomedical and industrial applications generating significant societal and economic benefits. However, such innovation increases human exposure to these substances through inhalation, ingestion or dermal contact raising public health concerns. Furthermore, the NMs’ specific physicochemical properties, that confer them unique beneficial characteristics, can also elicit nano-bio interactions leading to toxicity and concerns for public health. In addition, such properties can be affected by the surrounding matrix, particularly when incorporated in complex matrices such as food products, leading to secondary features potentially more relevant than primary characteristics for determining their toxicological outcome. These nano specific issues raise the question of whether the NMs may produce adverse outcomes that are not accounted for when using conventional toxicological approaches to assess their safety.
Such uncertainties about the safety of NMs for human health and the environment may hamper a faster and more widespread exploration of their potentials. In response, the NMs definition has evolved, and nanotoxicology has developed towards new and more integrative approach methods to support regulatory and policy actions.
This book provides a perspective on recent developments in the synthesis, application, and characterization of NMs and the related nanotechnologies, focusing on nanotoxicology for their accurate safety assessment early in the product development stage. The use of complex in vitro models, including multicellular systems and organoids, and “omics-based” approaches, such as transcriptomics or epigenomics, have greatly contributed to an in-depth understanding of the cellular and molecular mechanisms behind some NMs toxicity. Such mechanistic knowledge is equally addressed in this book and has set the basis for a predictive nanotoxicology approach building on adverse outcome pathways. In addition, considering the knowledge provided by the above-mentioned approaches, insights into risk assessment, standardization, and regulation of NMs are also included.
Incorporating adequate nanosafety assessment early in the life-cycle of NMs will allow the implementation of the safe and sustainable-by-design paradigm enabling safety to keep pace with innovation.
Chapters 10 and 15 are available open access under a Creative Commons Attribution 4.0 International License via link.springer.com.